Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (187)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (412)
  2. Solid Tumor Oncology Division (412)
  3. Thoracic Oncology (412)
  4. GSK Faculty (140)
  5. Department of Pathology and Laboratory Medicine (112)
  6. Weinberg Fellows (103)

More Groups

People
  1. Hira Rizvi (97)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (67)
  5. Jedd Wolchok (53)
  6. Gregory Riely (49)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (34)
  5. 2021 (40)
  6. 2020 (55)

More Years

Publications
  1. Journal of Clinical Oncology (91)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (96)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (57)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (412)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC
    Meeting Abstract

    Rizvi, H.; Plodkowski, A. J.; Tenet, M.; Halpenny, D.; Long, N.; Sauter, J. L.; Sanchez-Vega, F.; Chatila, W. K.; Schultz, N.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab (Nivo) + ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC): Safety analysis and patient-reported outcomes (PROs) from CheckMate 227
    Meeting Abstract

    Reck, M.; Hellmann, M. D.; Paz-Ares, L. G.; Ramalingam, S. S.; Brahmer, J. R.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F. E.; Borghaei, H.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Imaging of tumor infiltrating T cells with an anti-CD8 minibody (Mb) 89Zr-IAB22M2C, in advanced solid tumors
    Meeting Abstract

    Postow, M. A.; Harding, J. J.; Hellmann, M. D.; Gordon, M. S.; Tsai, F.; Donoghue, J. A. O.; Lewis, J. S.; Wu, A. M.; Le, W.; Korn, R. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutation burden and efficacy of targeted therapy in patients with EGFR mutant lung cancers
    Meeting Abstract

    Offin, M. D.; Rizvi, H.; Tenet, M.; Ni, A.; Sanchez Vega, F.; Kris, M. G.; Rudin, C. M.; Riely, G. J.; Yu, H. A.; Hellmann, M. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers
    Meeting Abstract

    Lai, W. C. V.; Feldman, D. L.; Buonocore, D. J.; Brzostowski, E. B.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Sabari, J. K.; Offin, M. D.; Kris, M. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L) 1 therapy
    Meeting Abstract

    Gandhi, L.; Janne, P. A.; Opyrchal, M.; Ramalingam, S. S.; Rybkin, I. I.; Hafez, N.; Raez, L. E.; Gabrilovich, D.; Wang, F.; Ordentlich, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Response and durability of anti-PD-(L) 1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression
    Meeting Abstract

    Gainor, J. F.; Rizvi, H.; Jimenez Aguilar, E.; Mooradian, M.; Lydon, C. A.; Anderson, D.; Tenet, M.; Sauter, J. L.; Mino-Kenudson, M.; Shaw, A. T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • 4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
    Meeting Abstract

    Felip, E.; Hellmann, M. D.; Hui, R.; Carcereny, E.; Leighl, N. B.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227
    Meeting Abstract

    Borghaei, H.; Hellmann, M. D.; Paz-Ares, L. G.; Ramalingam, S. S.; Reck, M.; O'Byrne, K. J.; Bhagavatheeswaran, P.; Nathan, F. E.; Brahmer, J. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC
    Meeting Abstract

    Arbour, K. C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Bernal, G. M.; Chaft, J. E.; Ferrara, R.; Lai, W. C. V.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save